Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations

Accompanying the increased use of biological and non-biological antirheumatic drugs, a greater number of cases of hepatitis B virus (HBV) reactivation have been reported in inactive hepatitis B surface antigen (HBsAg) carriers and also in HBsAg-negative patients who have resolved HBV infection. The...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:World journal of gastroenterology : WJG Ročník 21; číslo 36; s. 10274
Hlavní autoři: Mori, Shunsuke, Fujiyama, Shigetoshi
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 28.09.2015
Témata:
Antirheumatic Agents - adverse effects
Antiviral Agents - therapeutic use
Hepatitis B - diagnosis
Hepatitis B - epidemiology
Hepatitis B - immunology
Hepatitis B - prevention & control
Hepatitis B - virology
Hepatitis B virus - drug effects
Hepatitis B virus - immunology
Hepatitis B virus - pathogenicity
Humans
Immunocompromised Host
Prevalence
Recurrence
Rheumatic Diseases - diagnosis
Rheumatic Diseases - drug therapy
Rheumatic Diseases - epidemiology
Rheumatic Diseases - immunology
Risk Assessment
Risk Factors
Virus Activation - drug effects
Reactivation
Resolved hepatitis B virus infection
Hepatitis B virus
Occult hepatitis B virus carrier
Antirheumatic therapy
ISSN:2219-2840, 2219-2840
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Accompanying the increased use of biological and non-biological antirheumatic drugs, a greater number of cases of hepatitis B virus (HBV) reactivation have been reported in inactive hepatitis B surface antigen (HBsAg) carriers and also in HBsAg-negative patients who have resolved HBV infection. The prevalence of resolved infection varies in rheumatic disease patients, ranging from 7.3% to 66%. Through an electronic search of the PubMed database, we found that among 712 patients with resolved infection in 17 observational cohort studies, 12 experienced HBV reactivation (1.7%) during biological antirheumatic therapy. Reactivation rates were 2.4% for etanercept therapy, 0.6% for adalimumab, 0% for infliximab, 8.6% for tocilizumab, and 3.3% for rituximab. Regarding non-biological antirheumatic drugs, HBV reactivation was observed in 10 out of 327 patients with resolved infection from five cohort studies (3.2%). Most of these patients received steroids concomitantly. Outcomes were favorable in rheumatic disease patients. A number of recommendations have been established, but most of the supporting evidence was derived from the oncology and transplantation fields. Compared with patients in these fields, rheumatic disease patients continue treatment with multiple immunosuppressants for longer periods. Optimal frequency and duration of HBV-DNA monitoring and reliable markers for discontinuation of nucleoside analogues should be clarified for rheumatic disease patients with resolved HBV infection.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2219-2840
2219-2840
DOI:10.3748/wjg.v21.i36.10274